Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Immune Therapeutics, Inc. (IMUN : OTC)
 
 • Company Description   
Forte Biotechnology Intl Corp is a biotechnology company. Its goal is to acquire late stage modulator drugs and immune modulator biopharmaceuticals for cancer, chronic inflammation, pain and neurodegenerative disease in companion pets. Forte Biotechnology Intl Corp, formerly known as Immune Therapeutics Inc., is based in Fort Collins Colorado.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.00 Daily Weekly Monthly
20 Day Moving Average: 3,591 shares
Shares Outstanding: 0.48 (millions)
Market Capitalization: $0.96 (millions)
Beta: 0.98
52 Week High: $10.00
52 Week Low: $1.02
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 15.61% 30.19%
12 Week 25.00% 37.41%
Year To Date -33.11% -18.27%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2431 ALOMA AVENUE SUITE 124
-
WINTER PARK,FL 32792
USA
ph: 888-613-8802
fax: -
mmcenroe@tiberend.com http://www.immunetherapeutics.com
 
 • General Corporate Information   
Officers
Kevin Phelps - Chief Executive Officer; Chief Financial Officer a
Roscoe Moore - Chairman
Roscoe Moore - Director
Michael Sander - Director
Jack Brewer - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45252A305
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 0.48
Most Recent Split Date: 5.00 (0.00:1)
Beta: 0.98
Market Capitalization: $0.96 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: 0.27
Price / Sales: -
EPS Growth
vs. Year Ago Period: -10,680.00%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -2.58
12/31/21 - -38.46
09/30/21 - -28.10
ROA
03/31/22 - 14.36
12/31/21 - 244.75
09/30/21 - 421.92
Current Ratio
03/31/22 - 0.07
12/31/21 - 0.28
09/30/21 - 0.26
Quick Ratio
03/31/22 - 0.07
12/31/21 - 0.28
09/30/21 - 0.26
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -21.80
12/31/21 - -16.49
09/30/21 - -16.07
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©